Most adults in the UK under the age of 40 will now be offered an alternative to the Oxford-AstraZeneca vaccine, due to a link with rare blood clots.
Whilst the risk of clots is extremely low, it is found to be slightly higher amongst younger age groups.
From London, Benji Hyer reports.
IN: The UK's medicines
OUT: SOC
DUR: 34 secs